Today, the Danish pre-clinical contract research organization (“CRO”), Scantox A/S (“Scantox” or the “Company”) announced that it has been acquired by the leading Nordic healthcare investment company, Impilo, together with the management team of Scantox. The Company is formerly known as Charles River Copenhagen A/S and will today be renamed to Scantox A/S and continue its business operations as a fully independent company.
Founded in 1977, Scantox is a market leading GLP (“Good Laboratory Practice”) accredited CRO, providing pre-clinical research services, including regulatory in-vivo toxicology studies, that are critical to any drug development process. Scantox plays a vital role in the Nordic pharma and biotech community, where the Company has established deep relationships and enjoys a broad and loyal customer base, leveraging its strong track-record and more than 40 years of scientific experience.
Through the partnership with Impilo, Scantox will seek to further strengthen and expand its geographic footprint as well as its service offering, to successfully support drug development efforts for both local and global companies in the pharma, biotech, and medical device sectors.
Jeanet Løgsted, CEO of Scantox, says: “We have been given a unique opportunity together with Impilo to continue our business operations as an independent company and we look forward to once again position us as a market leader within pre-clinical research. We have assembled a strong team and I am confident that both existing and new clients will benefit from our vast experience in the field. During the last months we have experienced a fantastic support and dedication from our customers and staff. We will use this and together with Impilo build an even stronger pre-clinical brand beneficial for all clients within the pharma, biotech and medical device sectors.”
“As a long-term dedicated health care investor, Impilo is excited to support Scantox on its future journey and sees great potential for the Company as an independent pre-clinical CRO. We are truly impressed by the management team and its strong commitment to Scantox and its customers”, says Nicholas Hooge, Partner at Impilo and Head of its Danish operations, and continues: “Impilo has been attracted by the broader pre-clinical CRO market for years due to its strong underlying growth fundamentals and its critical role in the drug development process. In addition, we see significant potential to drive further consolidation in the industry going forward.”
About Scantox A/S
Founded in 1977, Scantox is a Danish GLP accredited pre-clinical CRO located outside of Copenhagen, providing toxicology studies as well as exploratory in-vivo work and disease models. In addition, the Company performs various histology and pathology services. Scantox was most recently a part of Charles River Laboratories. Visit us at www.scantox.com
For further information, please contact:
Nicholas Hooge, Partner at Impilo, +45 23 73 38 40, nicholas.hooge@impilo.se
Jeanet Løgsted, CEO of Scantox A/S, +45 56 86 15 00, jln@scantox.com
News
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.